Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 11/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16348540 | 0.89 | DAO (0.53) | PRKCQDAOGRIN1GRIN2BPRKCA | |
| SCHEMBL11511885 | 0.82 | DAO (0.58) | PRKCQDAOPRKCAKMT2AADORA3 | |
| SCHEMBL30257859 | 0.80 | DAO (0.55) | PRKCQDAOPRKCAADORA3ALDH1A1 | |
| SCHEMBL30615567 | 0.77 | DAO (0.47) | PRKCQDAOGRIN1GRIN2BPRKCA | |
| SCHEMBL30615537 | 0.77 | PRKCQ (0.48) | PRKCQDAOGRIN1GRIN2BPRKCA | |
| SCHEMBL21464054 | 0.77 | PRKCQ (0.48) | PRKCQDAOGRIN1GRIN2BPRKCA | |
| SCHEMBL30615338 | 0.77 | PRKCQ (0.48) | PRKCQDAOGRIN1GRIN2BPRKCA | |
| SCHEMBL21463894 | 0.77 | DAO (0.49) | DAOGRIN1GRIN2BKMT2AADORA3 | |
| SCHEMBL30615461 | 0.77 | DAO (0.49) | DAOGRIN1GRIN2BKMT2AADORA3 | |
| SCHEMBL21463768 | 0.77 | PRKCQ (0.50) | PRKCQDAOPRKCAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |